Background {#Sec1}
==========

Acute kidney injury (AKI) affects \> 50% of patients in the intensive care unit (ICU) \[[@CR1]\]. It is associated with an increased risk of complications and mortality. Sepsis is particularly common but can be challenging to diagnose due to potentially misleading clinical signs and a limited number of confirmatory diagnostic tests in routine clinical practice \[[@CR2]\].

Over 150 sepsis biomarkers have been identified \[[@CR3]\]. C-reactive protein (CRP) is used mainly as a marker of inflammation. Measuring and charting CRP values can prove useful in determining disease progress or the effectiveness of treatments but it has limited ability to distinguish sepsis from other inflammatory conditions \[[@CR3], [@CR4]\]. Soluble urokinase-type plasminogen activator receptor (suPAR) is one of several newer sepsis markers that has been investigated in recent years \[[@CR5]--[@CR8]\]. SuPAR is the soluble form of the cell membrane-bound urokinase plasminogen activator receptor (uPAR) which is expressed on various cell types, including neutrophils, lymphocytes, monocytes, endothelial cells and tumour cells. After cleavage from the cell surface, suPAR is released into the blood and most human body fluids. When inflammatory cells are activated by cytokines, the expression of uPAR is up-regulated, thus increasing the serum levels of suPAR, too \[[@CR9]\].

Several studies have shown higher systemic suPAR concentrations in critically ill patients compared to healthy controls, and in patients with infections compared to those without \[[@CR5], [@CR7], [@CR8], [@CR10]\]. However, a systematic review of relevant papers published until May 2011 reported that the diagnostic value of suPAR was low in critically ill patients with sepsis \[[@CR11]\]. A subsequent meta-analysis in 2016 concluded that suPAR had a role as a biomarker for the diagnosis and prognosis of bacterial infections but was relatively ineffective for differentiating sepsis from systemic inflammation \[[@CR12]\]. Both meta-analyses were limited by inclusion of heterogenous patient populations with varying acute and chronic illnesses. Whether there is a role for suPAR in critically ill patients with AKI is unknown.

Methods {#Sec2}
=======

Aims {#Sec3}
----

The aims of our study were: a) to describe serial systemic suPAR values in patients with severe AKI, including patients on continuous renal replacement therapy (CRRT); b) to explore whether suPAR was removed during CRRT; c) to investigate a potential association between suPAR and CRP, and d) to compare suPAR and CRP as diagnostic markers of infection in patients with AKI.

Design {#Sec4}
------

We performed a prospective observational study between April 2013 and April 2014.

Setting {#Sec5}
-------

Guy's & St Thomas' NHS Foundation Hospital is a tertiary care centre with a 43-bed, level 3 multi-disciplinary adult intensive care unit (ICU).

Patient population {#Sec6}
------------------

We recruited critically ill adult patients (≥18 years) with AKI stage 2 or 3 as per serum creatinine criteria of the Kidney Disease Improving Global Outcome classification \[[@CR13]\]. The lowest serum creatinine in the preceding 12 months prior to hospitalisation was used as a baseline value; if not available, patients were excluded. Other exclusion criteria were: AKI stage 2/3 present for more than 36 h, pre-existing dialysis dependent renal failure, or an expected life expectancy \< 48 h. We also excluded patients in whom serial blood sampling was not desirable (ie. Jehovah's witness, patients with haemoglobin \< 70 g/L).

Collection of samples {#Sec7}
---------------------

Samples for serum suPAR were collected at baseline and 22-26 h, 46-50 h, 94-98 h and 142-146 h after enrolment. Serum CRP was measured daily throughout the 6-day study period. In patients receiving CRRT, effluent samples were collected at the same time points for measurement of suPAR. All samples were processed and stored in dedicated research freezers at -80 °C until batch analysis at the end of the study.

Collection of clinical data {#Sec8}
---------------------------

We collected baseline demographics, Acute Physiology and Chronic Health Evaluation (APACHE) II score and Sequential Organ Failure Assessment (SOFA) score on admission to ICU. Patients were categorised as having an infection if they had documented clinical signs combined with positive microbiology or imaging results supporting the diagnosis of an infection.

Laboratory analyses {#Sec9}
-------------------

Serial suPAR concentrations were measured by enzyme-linked immunosorbent assay (ELISA) using the commercially available suPARnostic® ELISA Kit manufactured by ViroGates, Denmark. Samples were tested in singlets with inter-plate variation of 6%. CRP was measured using a latex enhanced immunoturbidimetric method on the Siemens Advia 2400 \[analytical range: 4--336 mg/L and reference range: \< 10 mg/L\].

Statistics {#Sec10}
----------

Patient characteristics, suPAR and CRP levels were summarised as frequency (percentage), mean \[standard deviation (SD)\] or median \[interquartile range (IQR)\], as appropriate. The relationship between suPAR and CRP at each time point was explored using Pearson correlation. Additionally, the correlations between suPAR and previous day CRP, CRP and previous day suPAR, and changes of suPAR and CRP from their respective previous measurement were calculated.

We compared the characteristics of patients who did and did not develop infections using the Chi-squared, Fisher's exact and t-tests, as approriate. SuPAR and CRP levels of both groups were compared using Mann-Whitney tests, and areas under the receiver operating characteristics curves (AUC) were calculated to assess the ability of suPAR and CRP to discriminate between patients with an established infection and those who did not develop an infection during the study period.

Results {#Sec11}
=======

We analysed the data of 55 patients with AKI stage 2 or 3 of whom 43 received CRRT during the 6-day study period. The mean age was 60.5 (15.9) years and 61.8% were male (Table [1](#Tab1){ref-type="table"}). The majority were caucasian (60%), followed by Afro-Carribean (16.4%) and Asian (10.9%).Table 1Baseline demographicsParameterTotal cohort (*n* = 55)Age \[years\], mean (SD)60.5 (15.9)Male gender, n (%)34 (61.8%)Ethnicity Caucasian60% Afro-Caribbean16.4% Asian10.9% Other12.7%Diabetes Mellitus18 (32.7%)Any CKD19 (34.6%)CKD stages 10 22 (3.6%) 3a7 (12.7%) 3b7 (12.7%) 42 (3.6%) 51 (1.8%)ICU admission diagnosis, n (%) Post-major surgery19 (34.5%) Sepsis16 (29%) Respiratory failure6 (10.9%) Vasculitis2 (3.6%) Multi-organ failure4 (7.2%) Neurological emergency2 (3.6%) Cardiac arrest1 (1.8%) Other5 (9.1%)Severity of illness on admission to ICU APACHE II score, mean (SD)19.4 (5.2) SOFA score, mean (SD)8.1 (2.4)*Abbreviations*: *APACHE* Acute Physiology and Chronic Health Evaluation, *CKD* chronic kidney disease, *SD* standard deviation, *SOFA* sequential organ failure assessment, *ICU* Intensive care unit

Biomarker results {#Sec12}
-----------------

Mean CRP levels increased between day of recruitment and day 1 and then declined from day 3 onwards (Table [2](#Tab2){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}). In contrast, the systemic suPAR levels tended to remain stable or increase slighty across the 6-day study period (Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). In patients treated with CRRT, suPAR was not detectable in the effluent fluid.Table 2Correlations between mean systemic suPAR and CRP valuessuPAR \[ng/ml\] mean (SD)CRP \[mg/L\] mean (SD)CorrelationDay of enrolment11.0 (7.6)176.0 (113.2)*r* = 0.234 *p* = 0.095Day 111.7 (7.7)199.5 (106.0)*r* = 0.092 *p* = 0.519Day 212.5 (8.9)195.5 (105.6)*r* = 0.018 *p* = 0.897Day 3--160.2 (88.5)Day 412.6 (9.0)142.3 (88.0)*r* = 0.012 *p* = 0.935Day 5--126.1 (80.6)Day 613.4 (9.0)115.6 (74.2)*r* = 0.039 *p* = 0..801*Abbreviations*: *suPAR* soluble urokinase-type plasminogen activator receptor, *CRP* C-reactive protein, *r* regression, *SD* standard deviationFig. 1Serial serum CRP concentrations. Abbreviations: CRP = C-reactive proteinFig. 2Serial systemic suPAR concentrations. Abbreviations: suPAR = soluble urokinase-type plasminogen activator receptor

Correlation between suPAR and CRP {#Sec13}
---------------------------------

On the day of enrolment (ie. day 0), there was a weak to moderate correlation between systemic suPAR and CRP concentrations (*r* = 0.234) but this was not statistically significant (*p* = 0.095) (Table [2](#Tab2){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}). After day 0, there was no significant correlation between CRP and suPAR results.Fig. 3Scatter plots of daily suPAR and CRP values. Abbreviations: suPAR = soluble urokinase-type plasminogen activator receptor in ng/ml; CRP = C-reactive protein in mg/L

To allow for the possibility that CRP or suPAR concentrations changed at different rates, the correlations between values on consecutive days were calculated. No significant correlation between CRP and suPAR concentrations was detected (Table [3](#Tab3){ref-type="table"}). However, when evaluating the change in suPAR and CRP values from the respective previous measurement, a weak correlation between change in suPAR and CRP from day 0 to day 1 (*r* = 0.298, *p* = 0.037) and day 1 to day 2 (*r* = 0.310, *p* = 0.029) was noted (Table [3](#Tab3){ref-type="table"}). There was no correlation at any later time point.Table 3Correlations between systemic suPAR and CRP values on different daysCorrelation between suPAR result and previous day CRP valueCorrelation between CRP value and previous day suPAR resultCorrelation between change in suPAR and change in CRP valuesDay 1*r* = 0.228 *p* = 0.108*r* = 0.042 *p* = 0.767*r* = 0.298 *p* = 0.037Day 2*r* = − 0.026 *p* = 0.856*r* = 0.090 *p* = 0.518*r* = 0.310 *p* = 0.029Day 3--*r* = − 0.104 *p* = 0.491--Day 4*r* = − 0.049 *p* = 0.747--*r* = 0.232 *p* = 0.129Day 5--*r* = 0.036 *p* = 0.819--Day 6*r* = 0.048 *p* = 0.761--*r* = −0.166 *p* = 0.299*Abbreviations*: *suPAR* soluble urokinase-type plasminogen activator receptor, *CRP* C-reactive protein, *r* regression

Role of suPAR and CRP as markers of infection {#Sec14}
---------------------------------------------

There were no significant baseline differences between patients with and without an infection during the 6-day study period (Table [4](#Tab4){ref-type="table"}). Values of suPAR were significantly higher in those with an infection across all time points but there was no difference in CRP results (Table [5](#Tab5){ref-type="table"}). In patients with an infection, the respective AUCs of suPAR on the day of infection were higher than those of CRP values (Table [6](#Tab6){ref-type="table"}).Table 4Characteristics of patients with and without infectionParameterNo infection during 6-day study period *n* = 19Infection during 6-day study period *n* = 36*p*-valueAge, mean (SD)61.5 (16.7)60.0 (15.7)0.75Male sex, n (%)12 (63.2)22 (31.1)0.88Ethnicity, n (%) Caucasian11 (57.9)22 (61.1)0.69 Afro-Carribean4 (21.1)5 (13.9) Asian1 (5.3)5 (13.9) Other3 (15.8)4 (11.1)BMI, mean (SD)27.4 (5.5)29.2 (8.9)0.46SOFA score on admission to ICU, median (IQR)8 (7--10)8 (7--9)0.43Diabetes Mellitus4 (21.1)14 (38.9)0.23Any CKD7 (36.8)12 (33.3)0.99*Abbreviations*: *BMI* body mass index, *ICU* intensive care unit, *IQR* interquartile range, *SD* standard deviationTable 5Comparison of suPAR and CRP values in patients with and without infectionssuPAR \[ng/ml\]CRP \[mg/L\]No infection during 6 day study periodInfection during 6 day study period*p*-valueNo infection during 6 day study periodInfection during 6 day study period*p*-valuenMedian (IQR)nMedian (IQR)nMedian (IQR)nMedian (IQR)Day of enrolment196.2 (4.2--9.2)3611.0 (6.5--16.1)0.0216124 (60--238)36162 (105--286)0.50Day 1197.2 (4.5--10.1)3511.4 (7.1--14.50.0218181 (80--241)35191 (118--280)0.33Day 2188.1 (3.9--11.3)3410.8 (6.8--14.6)0.0419171 (51--282)35204 (121--254)0.49Day 316125 (67--212)32174 (98--227)0.32Day 4176.7 (4.1--10.6)3411.7 (8.2--18.5)0.0217135 (74--202)31109 (82--178)0.94Day 51598 (46--196)30105 (63--169)0.85Day 6188.4 (5.3--14.1)3012.6 (8.2--22.4)0.041589 (71--184)32101 (61--153)0.65*Abbreviations*: *suPAR* soluble urokinase-type plasminogen activator receptor, *CRP* C-reactive protein, *IQR* interquartile rangeTable 6Area under the receiver operating curves of suPAR and CRP for diagnosing an established infectionsuPARCRPnAUC95% CInAUC95% CIDay 0430.730.57--0.89400.580.39--0.77Day 1420.720.56--0.89410.580.40--0.77Day 2440.690.52--0.56450.540.35--0.73Day 3420.580.38--0.77Day 4470.710.55--0.87450.480.29--0.68Day 5420.490.29--0.68Day 6480.6740.51--0.83470.460.27--0.65*Abbreviations*: *suPAR* soluble urokinase-type plasminogen activator receptor, *CRP* C-reactive protein, *CI* confidence interval, *AUC* area under receiver operating characteristics curve

Role of suPAR and CRP as predictors of infection {#Sec15}
------------------------------------------------

The majority of infections were diagnosed before of shortly after admission to the ICU. Thirty six patients had an infection during the study period of whom 5 (13.9%) were diagnosed prior to enrolment and 13 (36%) on day of enrolment; the remaining 18 patients (50%) were diagnosed later. Following exclusion of patients with an infection before or on day of ICU admission, the AUC of suPAR on day 0 for predicting an infection later was 0.62 (95% CI 0.43--0.80) compared to 0.50 (0.29--0.71) for CRP.

Discussion {#Sec16}
==========

Our results show that CRP was a poor marker of infection in patients with severe AKI whereas suPAR had a stronger association with the development of an infection. We also confirmed that serum suPAR was not removed during CRRT.

Infections are the major causes of morbidity and mortality in patients with AKI \[[@CR14]\]. Accurate and timely diagnosis is essential to enable clinicians to initiate appropriate and effective antimicrobial therapy early. The tools used by clinicians, namely clinical signs, inflammatory markers and imaging techniques, have important limitations \[[@CR15]\].

SuPAR has emerged as a potential sepsis biomarker \[[@CR2], [@CR5], [@CR6]\]. Under normal physiological conditions, suPAR is predominantly expressed by neutrophils, monocytes, macrophages and activated T-cells, and its serum concentration is relatively stable throughout the day \[[@CR9]\]. In healthy adults, mean suPAR concentrations of 2000 pg/ml have been reported \[[@CR16]\]. SuPAR has a molecular mass of approximately 55-60 kDa. While the membrane-bound uPAR appears to facilitate phagocytosis of bacteria, suPAR has chemotactic properties and facilitates recruitment of neutrophils and monocytes \[[@CR8], [@CR11], [@CR17], [@CR18]\]. Apart from infections, serum concentrations of suPAR may also be increased during inflammatory conditions, such as arthritis, cancer and liver disease \[[@CR9]\]. Not surprisingly, several studies have shown that critically ill patients with systemic inflammatory response syndrome (SIRS), bacteraemia or sepsis had significantly higher suPAR results than healthy controls but the accuracy of suPAR to differentiate sepsis from SIRS was low \[[@CR5], [@CR12], [@CR19]--[@CR22]\].

Data on the role of suPAR in patients with renal disease are limited to patients with specific types of chronic kidney disease (CKD) like focal segmental glomerulosclerosis, diabetic nephropathy and lupus nephritis where plasma suPAR appears to have a pathological role resulting in proteinuria and renal scarring \[[@CR23]--[@CR26]\]. In a recent prospective observational trial in 107 consecutive elective cardiac surgery patients, suPAR levels were predictive of the development of AKI after surgery after exclusion of patients with pre-existing CKD \[[@CR27]\]. Finally, in patients with cardiovascular risk factors, suPAR levels have been found to be associated with a more rapid decline in glomerular filtration rate \[[@CR23]\].

This is the first study that focused on the role of suPAR as a marker of infection in patients with severe AKI. The main result was that suPAR only had moderate sensitivity and specificity but performed better than CRP. This is an important finding since CRP is often used in clinical practice as an aid to diagnose and monitor the course of an infection. We acknowledge that further research is necessary to confirm these findings. It will also be important to compare the performance of suPAR with that of procalcitonin (PCT), and to evaluate the role of suPAR in combination with existing severity of illness scores.

We acknowledge other potential limitations. First, as a single centre study, there is reduced generalisability of the results to centres with a different patient-case mix. Second, we categorised patients as having an infection based on a retrospective review of all clinical data, laboratory results and microbiological reports. It is possible that patients with an infection were missed or mis-classified. Third, suPAR concentrations can be affected by other inflammatory conditions, cancer and liver disease. In our analysis, we did not control for these potential confounders. Fourth, we only enrolled patients with AKI stage 2 and 3 and did not distinguish between different types and aetiologies of AKI, and it is possible that the performance of suPAR varies depending on the aetiology or stage of AKI. Finally, our sample size was relatively small. Larger studies are necessary to validate our findings, to determine a diagnostic cut-off of suPAR in patients with AKI and to explore whether suPAR levels correlate with the clinical course following an infection.

Conclusions {#Sec17}
===========

Our study showed that suPAR concentrations had better diagnostic and predictive value than CRP to detect infections in critically ill patients with severe AKI. Larger studies are necessary to confirm our findings.
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